Claims
- 1. An isolated polypeptide comprising SEQ ID NO: 201.
- 2. An immunogenic composition comprising at least one polypeptide according to claim 1 and a physiologically acceptable carrier.
- 3. An immunogenic composition comprising at least one polypeptide according to claim 1 and a non-specific immune response enhancer.
- 4. A fusion protein comprising at least one polypeptide according to claim 1.
- 5. An immunogenic composition comprising at least one fusion protein according to claim 4 and a physiologically acceptable carrier.
- 6. An immunogenic composition comprising at least one fusion protein according to claim 4 and a non-specific immune response enhancer.
- 7. An isolated polypeptide comprising an immunogenic portion of SEQ ID NO: 201.
- 8. An immunogenic composition comprising at least one polypeptide according to claim 7 and a physiologically acceptable carrier.
- 9. An immunogenic composition comprising at least one polypeptide according to claim 7 and a non-specific immune response enhancer.
- 10. A fusion protein comprising at least one polypeptide according to claim 7.
- 11. An immunogenic composition comprising at least one fusion protein according to claim 10 and a non-specific immune response enhancer.
- 12. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of sequences having at least 75% identical residues to SEQ ID NO: 201, wherein the polypeptide exhibits the same immunological characteristics as a polypeptide of SEQ ID NO: 201.
- 13. An immunogenic composition comprising at least one polypeptide according to claim 12 and a physiologically acceptable carrier.
- 14. An immunogenic composition comprising at least one polypeptide according to claim 12 and a non-specific immune response enhancer.
- 15. A fusion protein comprising at least one polypeptide according to claim 12.
- 16. An immunogenic composition comprising at least one fusion protein according to claim 15 and a non-specific immune response enhancer.
- 17. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of sequences having at least 90% identical residues to SEQ ID NO: 201, wherein the polypeptide exhibits the same immunological characteristics as a polypeptide of SEQ ID NO: 201.
- 18. An immunogenic composition comprising at least one polypeptide according to claim 17 and a physiologically acceptable carrier.
- 19. An immunogenic composition comprising at least one polypeptide according to claim 17 and a non-specific immune response enhancer.
- 20. A fusion protein comprising at least one polypeptide according to claim 17.
- 21. An immunogenic composition comprising at least one fusion protein according to claim 20 and a non-specific immune response enhancer.
REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. application Ser. No. 09/095,855, filed Jun. 11, 1998, which is a continuation-in-part of U.S. patent application Ser. No. 08/997,362, filed Dec. 23, 1997, now U.S. Pat. No. 5,985,287 which is a continuation-in-part of U.S. patent application Ser. No. 08/873,970, filed Jun. 12, 1997, now U.S. Pat. No. 6,001,361 which is a continuation-in-part of U.S. patent application Ser. No. 08/705,347, filed Aug. 29, 1996.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
3956481 |
Jolles et al. |
May 1976 |
A |
4036953 |
Adam et al. |
Jul 1977 |
A |
4716038 |
Stanford et al. |
Dec 1987 |
A |
4724144 |
Rook et al. |
Feb 1988 |
A |
5599545 |
Stanford et al. |
Feb 1997 |
A |
Foreign Referenced Citations (9)
Number |
Date |
Country |
0763361 |
Mar 1997 |
EP |
9007935 |
Jul 1990 |
WO |
9101751 |
Feb 1991 |
WO |
9102542 |
Mar 1991 |
WO |
9208484 |
Mar 1992 |
WO |
9208488 |
May 1992 |
WO |
9316727 |
Sep 1993 |
WO |
9406466 |
Mar 1994 |
WO |
9526742 |
Oct 1995 |
WO |
Non-Patent Literature Citations (4)
Entry |
R.G. White et al., “Correlation of Adjuvant Activity and Chemical Structure of Wax D Fractions of Mycobacteria,” Immunology 7, pp. 158-171, 1964. |
R.G. White, “Characterization of Micobacterial Components of Adjuvant Mixtures,” Symposium Series Immunobiol. Standard 6, pp. 49-58, 1967. |
R.G. White et al., The Influence of Components of M. Tuberculosis and other Mycobacteria upon Antibody Production to Ovalbumin, Immunology I. pp. 54-66, 1958. |
Skinner, Immunization with Heat-Killed Mycobacterium vaccae Stimulates CD8+ Cytotoxic T Cells Specific for Macrophages Infected with Mycobacterium tuberculosis, Infection and Immunity 65:11, 4525-4530, 1997. |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
09/095855 |
Jun 1998 |
US |
Child |
09/205426 |
|
US |
Parent |
08/997362 |
Dec 1997 |
US |
Child |
09/095855 |
|
US |
Parent |
08/873970 |
Jun 1997 |
US |
Child |
08/997362 |
|
US |
Parent |
08/705347 |
Aug 1996 |
US |
Child |
08/873970 |
|
US |